Industry context
Horizon Therapeutics [HZNP]
Last Updated 16 Jan 2025 @ 16:00 (Exchange is closed)
Last: $116.30
0.00%
2.04 (↑)
GaG Algo Score™
v1.0
Short
2.04 (↑)
Medium
3.24 (↑)
Long
2.64 (↑)
Line
Pivot Data
Pivot Statistics
Insufficient pivot data for statistics.
Next Pivot Prediction Last: $116.30
Unable to generate prediction based on available data.
Little movement for Horizon Therapeutics.
Horizon Therapeutics (HZNP) stock price ended the session unchanged on Thursday after the stock unchanged $0 (0.00%) from the previous session on extraordinarily high volume. The stock held up slightly better than the falling NASDAQ (-0.46% down). With 23.92M shares traded, volume yesterday reached $2.78B. This was 0 shares the same as the prior day. Compared to the 10-day average of 6.97M shares, volume was more than the average.
Horizon Therapeutics signals
The last upturn is pushing the stock into overbought territory (RSI above 70) with a current RSI of 83.96, which traditionally suggests the stock may be overvalued in the short term. The price is above both the short- and long-term averages, and the short-term average is above the long-term average, confirming an established up-trend. Market in Equilibrium: A state of indecision prevails across all timeframes, with signals mixed in the short- (26.7%), medium- (26.7%), and long-term (26.7%) horizons. This balance between forces suggests a period of consolidation and the absence of a clear directional catalyst.
Horizon Therapeutics Support & Resistance Levels
The stock is trading above the closest support level at $113.00. approximately $3.30 (2.84%) away. This suggests it is currently acting as a floor, approaching it.The sup dis das support -
Horizon Therapeutics Evaluation
- Short score: 2.04
- Medium score: 3.24
- Long score: 2.64
Positioning pressure
Short interest pressure
Short interest
3.37%
Of outstanding shares
Short float
0.00%
Of tradable float
Days to cover
4.91
Short interest divided by average volume
Squeeze probability
-
+8.69% change
Short interest is worth monitoring, but the setup is not extreme.
Updated 2023-09-29Earnings quality
Earnings history
Reported quarters
12
EPS beats
9
EPS misses
3
Avg. surprise
6.65%
Horizon Therapeutics Public Limited Company Estimated Earnings vs Actual Earnings
Actual EPS
Estimated EPS
Beat
Q2/2021
Beat
Q3/2021
Beat
Q4/2021
Beat
Q1/2022
Miss
Q2/2022
Beat
Q3/2022
Beat
Q4/2022
Miss
Q1/2023
Beat
Q2/2023
Beat
Q3/2023
Horizon Therapeutics Public Limited Company Earnings History
| Date | Period | EPS estimate | Actual EPS | EPS surprise | Revenue estimate | Revenue actual | Revenue surprise |
|---|---|---|---|---|---|---|---|
| 2023-11-01 | Q3/2023 | $1.220 | $1.250 | Beat 2.46% | - | - | Waiting |
| 2023-08-08 | Q2/2023 | $1.120 | $1.200 | Beat 7.14% | 953.95M | 944.96M | Miss -0.94% |
| 2023-05-03 | Q1/2023 | $1.170 | $0.830 | Miss -29.06% | 915.71M | 832.06M | Miss -9.14% |
| 2023-03-01 | Q4/2022 | $1.090 | $1.210 | Beat 11.01% | 902.28M | 942.03M | Beat 4.41% |
| 2022-11-02 | Q3/2022 | $1.000 | $1.250 | Beat 25.00% | - | 925.36M | Waiting |
| 2022-08-03 | Q2/2022 | $1.350 | $1.070 | Miss -20.74% | - | 876.41M | Waiting |
| 2022-05-04 | Q1/2022 | $1.150 | $1.340 | Beat 16.52% | 729.94M | 885.25M | Beat 21.28% |
| 2022-03-01 | Q4/2021 | $1.270 | $1.410 | Beat 11.02% | 870.95M | 1.01B | Beat 16.48% |
| 2021-11-03 | Q3/2021 | $1.540 | $1.750 | Beat 13.64% | 895.58M | 1.04B | Beat 15.79% |
| 2021-08-04 | Q2/2021 | $0.910 | $1.620 | Beat 78.02% | 679.30M | 832.55M | Beat 22.56% |
| 2021-05-05 | Q1/2021 | $0.0700 | $0.0300 | Miss -57.14% | 414.37M | 342.41M | Miss -17.37% |
| 2021-02-24 | Q4/2020 | $1.050 | $1.280 | Beat 21.90% | 590.63M | 745.31M | Beat 26.19% |
Analyst view
Analyst targets
Consensus
$127.15
Median
$126.50
Low
$110.00
High
$144.00
News flow
Latest company news
Market coverage
seekingalpha.com Amgen: MariTide's Progress, Reassessment Of The Horizon Acquisition Sep 25, 2025 reuters.com Amgen quarterly profit rises 15% as Horizon deal boosts results Feb 6, 2024 cnbc.com Cramer names biopharma companies to watch as industry mergers start to pile up Jan 5, 2024 seekingalpha.com 5 Biotech Acquisition Targets To Accumulate In 2024 Dec 21, 2023Company releases
Company context
Company profile
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Drug Manufacturers General
Currency
USD
Horizon Therapeutics Public Limited Company a biotechnology company focuses on the discovery development and commercialization of medicines that address critical needs for people impacted by rare autoimmune and severe inflammatory diseases The company operates in two segments Orphan and Inflammation Its portfolio comprises 12 medicines in the areas of rare diseases gout ophthalmology and inflammation It markets TEPEZZA teprotumumabtrbw for intravenous infusion KRYSTEXXA pegloticase injection for intravenous infusion RAVICTI glycerol phenylbutyrate oral liquid PROCYSBI cysteamine bitartrate delayedrelease capsules and granules for oral use ACTIMMUNE interferon gamma1b injection for subcutaneous use BUPHENYL sodium phenylbutyrate tablets and powder for oral use QUINSAIR levofloxacin solution for inhalation and UPLIZNA inebilizumabcdon injection for intravenous use The company also markets PENNSAID diclofenac sodium topical solution for topical use DUEXIS ibuprofenfamotidine tablets for oral use RAYOS prednisone delayedrelease tablets for oral use and VIMOVO naproxenesomeprazole magnesium delayedrelease tablets for oral use It has collaboration agreements with HemoShear Therapeutics LLC Alpine Immune Sciences Inc Halozyme Therapeutics Inc and Arrowhead Pharmaceuticals Inc The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019 Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin Ireland with additional offices in Deerfield Illinois Chicago Illinois Lake Forest Illinois South San Francisco California Washington DC Gaithersburg Maryland Rockville Maryland and Mannheim Germany
Navigation